KRAS mutations were also present in 3 (15%) of 20 tested patients with uterine cancer, in 5 (11%) of 46 tested patients with ovarian cancer, 2 (9%) of 22 assessed patients with NSCLC, 1 (6%) of 17 tested patients with breast cancer, 1 (5%) of 22 tested patients with melanoma, and in 1 (4%) of 28 tested patients with squamous cell cancer of head and neck (Figure 1B). This evidence concerns the gene KRAS and squamous cell carcinoma.